These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 10810428)
1. Administration of tamoxifen in the perioperative period to patients with breast carcinoma prolongs axillary fluid drainage. Kelessis NG; Vassilopoulos PP; Galanopoulou AV; Nessiotis AG; Stravolemos CM Anticancer Res; 2000; 20(2B):1245-8. PubMed ID: 10810428 [TBL] [Abstract][Full Text] [Related]
2. Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla? Martelli G; Miceli R; De Palo G; Coradini D; Salvadori B; Zucali R; Galante E; Marubini E Cancer; 2003 Mar; 97(5):1156-63. PubMed ID: 12599220 [TBL] [Abstract][Full Text] [Related]
3. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer. Brandt S; Kopp A; Grage B; Knabbe C Anticancer Res; 2003; 23(1A):223-9. PubMed ID: 12680217 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related]
5. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study. Martelli G; Miceli R; Costa A; Coradini D; Zurrida S; Piromalli D; Vetrella G; Greco M Cancer; 2008 Feb; 112(3):481-8. PubMed ID: 18098268 [TBL] [Abstract][Full Text] [Related]
6. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) and MUC1 from the axillary fluid drainage in patients after breast cancer surgery. Greenberg R; Barnea Y; Schneebaum S; Kashtan H; Kaplan O; Skornik Y Isr Med Assoc J; 2003 Sep; 5(9):649-52. PubMed ID: 14509156 [TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. Johansen J; Overgaard J; Overgaard M Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320 [TBL] [Abstract][Full Text] [Related]
8. The nature of tamoxifen action in the control of female breast cancer. Kodama M; Kodama T In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224 [TBL] [Abstract][Full Text] [Related]
9. Stroke risk and tamoxifen therapy for breast cancer. Geiger AM; Fischberg GM; Chen W; Bernstein L J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603 [TBL] [Abstract][Full Text] [Related]
10. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution. Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
12. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302 [TBL] [Abstract][Full Text] [Related]
13. Axillary lymph node metastases as the sole clinical site of occult breast carcinoma. Dragoumis DM; Tsiftsoglou AP; Sikou AD; Assimaki AS J Coll Physicians Surg Pak; 2008 Aug; 18(8):517-9. PubMed ID: 18798593 [TBL] [Abstract][Full Text] [Related]
14. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. ; Rudenstam CM; Zahrieh D; Forbes JF; Crivellari D; Holmberg SB; Rey P; Dent D; Campbell I; Bernhard J; Price KN; Castiglione-Gertsch M; Goldhirsch A; Gelber RD; Coates AS J Clin Oncol; 2006 Jan; 24(3):337-44. PubMed ID: 16344321 [TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905 [TBL] [Abstract][Full Text] [Related]
16. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients. Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621 [TBL] [Abstract][Full Text] [Related]
17. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer. Petrik DW; McCready DR; Sawka CA; Goel V J Surg Oncol; 2003 Feb; 82(2):84-90. PubMed ID: 12561062 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen treatment and new-onset depression in breast cancer patients. Lee KC; Ray GT; Hunkeler EM; Finley PR Psychosomatics; 2007; 48(3):205-10. PubMed ID: 17478588 [TBL] [Abstract][Full Text] [Related]
19. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer. Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP Menopause; 2009; 16(2):293-300. PubMed ID: 19034048 [TBL] [Abstract][Full Text] [Related]
20. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]